TTrialPathMatch Me to Trials
← Back to trials
RecruitingBreast NeoplasmsLiver NeoplasmsMetastasis

A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases

Eligible age

18–75 yrs

Accepts

Women

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a single-center, parallel-controlled clinical study designed to evaluate the safety, efficacy and impact on systemic anti-tumor immunity of a multi-mode integrated ablation system for the treatment of breast cancer liver metastases.

Sponsor: Ruijin Hospital

You may qualify if…

  • ✓ 1. Age 18-75 years, female gender;
  • ✓ 2. Pathologically confirmed breast cancer liver metastases, in patients who are unable to tolerate or refuse surgical resection;
  • ✓ 3. The number of lesions ≤ 3, with any single lesion diameter ≤ 4cm;
  • ✓ 4. At least an interval of 1 month since the last local treatment;
  • ✓ 5. Child-Pugh class A or B;
  • ✓ 6. ECOG PS score ≤2, with an expected survival of \>3 months.

You may not qualify if…

  • ✕ 1. Liver function Child-Pugh class C;
  • ✕ 2. Systemic widespread metastasis, with an expected survival of \< 3 months;
  • ✕ 3. History of esophageal (gastric fundus) variceal bleeding within the past month;
  • ✕ 4. Dysfunction or failure of vital organs;
  • ✕ 5. Presence of an active infection;
  • ✕ 6. Irreparable coagulation abnormality;
  • ✕ 7. Refractory massive ascites, pleural effusion or cachexia;
  • ✕ 8. Pregnancy, altered consciousness or patients unable to cooperate with treatment;

Source: ClinicalTrials.gov · NCT06567353 · last updated 2025-03-14

A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Live · TrialPath